Podcasts about namd

Medicaid is a program jointly funded by the federal and state governments. It provides health care coverage to nearly 80 million people, primarily those with low incomes, people who are living with disabilities or are in long-term care. On this episode we discussed the nuts and bolts of how Medicaid is financed and how states are handling some new challenges in the post-pandemic world. The pandemic affected both who Medicaid covered and the share paid by the federal and state governments.  In the first segment, NCSL's Kathryn Costanza was joined by Akeiisa Coleman from the Commonwealth Fund to break down the details of how the program is funded, including how the federal-state share is determined for each state. They also discussed the key drivers of cost in the Medicaid system. On the second segment, guests Neda Jasemi from the National Association of Medicaid Directors, and Robin Rudowitz from KFF talk about what they are hearing from Medicaid officials around the country. They discussed how the post-COVID unwinding of patients who had remained on the rolls during the pandemic had significant effects on the program. They also discussed steps states are taking to try to ensure access for Medicaid patients and how states are preparing for any changes in the program at the federal level. ResourcesCommonwealth Fund/MedicaidHealth Costs, Coverage and Delivery State Legislation Database, NCSLHow We Pay for MedicaidKFF/Medicaid“Medicaid Financing 101,” NCSL“Medicaid Toolkit,” NCSLNational Association of Medicaid Directors“Results from an Annual Medicaid Budget Survey for State Fiscal Years 2024 and 2025,” KFF“State Legislatures Address Medicaid Coverage and Payments in the 2024 Legislative Session,” NCSL“State Tax Actions: 2024,” NCSL“Top five Medicaid budget pressures for fiscal year 2025,” NAMD

Too busy to read the Lens? Listen to our weekly summary here! In this week's episode we discuss…Brolucizumab provided non-inferior outcomes compared to aflibercept in nAMD eyes with persistent retinal fluid, but was associated with more adverse ocular events.A case series study evaluated the ophthalmic complications associated with semaglutide and tirzepatide used for treatment of diabetes.The distinct ocular surface microbiome found in keratoconus patients may correlate with local immune dysregulation that contributes to disease pathogenesis.

Dr. Carlos Quezada-Ruiz is a Vitreoretinal Surgeon and Assistant Professor of Ophthalmology at the Instituto de Oftalmologia Fundación Conde de Valenciana's Retina Department in Mexico City. He also serves as the Senior Vice President of Clinical Research and Development and Therapeutic Area Head (Ophthalmology) at 4DMT, leading early- and late-stage clinical development teams focused on treating neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and geographic atrophy (GA). In addition to his active clinical practice, Dr. Quezada-Ruiz has spent the past decade as a Drug Developer, beginning at Genentech–Roche. There, he worked on the Ophthalmology management team as Group Medical Director of Clinical Science (Product Development). During his tenure, he led the design, execution, and analysis of U.S. and global registrational trials for multiple retinal diseases, including the nAMD global clinical development program for VABYSMO, resulting in U.S. and worldwide approvals. He also led the global clinical science team for SUSVIMO, supporting its initial global filing, FDA approval, and launch in nAMD; successfully navigated the U.S. voluntary recall and commercial relaunch; and oversaw the phase 3 DR/DME registrational program through execution, readout, and filing with the FDA in early 2024. Previously, Dr. Quezada-Ruiz led Medical Affairs efforts for the U.S. launch of Lucentis Prefilled Syringe (PFS) and the myopic choroidal neovascularization indication for LUCENTIS. Furthermore, Dr. Quezada-Ruiz contributed to diversity and inclusion strategies in the Ophthalmology Franchise—such as the AAO MOM program—and advanced personalized healthcare in retina at Genentech by helping design and develop predictive models that use machine learning and large language models to support both drug development and clinical practice. Dr. Quezada-Ruiz is a Fellow of the American Society of Retina Specialists, with over 13 years of clinical practice and research in vitreoretinal diseases and surgery. He earned his M.D. from Universidad Autónoma de Coahuila in his hometown of Torreón, Mexico. He completed fellowships in Vitreoretinal Surgery, Ocular Pathology Research, and Vitreoretinal Surgery Research at Universidad Nacional Autónoma de México, McGill University, and the California Retina Research Foundation, respectively. In 2023, he completed an Executive Education program (CIBE) at Columbia Business School. His accolades include the 2023 Roche Award of Excellence in recognition of outstanding contributions to Roche Pharmaceuticals (“Vabysmo and Beyond”), Genentech's 2023 Medical Excellence Award, the 2019 American Society of Retina Specialists Senior Honor Award, the 2016 ASRS Honor Award, the 2013 Gillingham Pan-American Fellowship by the Pan-American Association of Ophthalmology and The Retina Research Foundation of Houston, Texas, and the 2013 Leonard Ellen Ocular Pathology Award by the Royal Victoria Hospital Foundation. On a personal note, Dr. Quezada-Ruiz is married to Cecy—formerly a marketing specialist at The Coca-Cola Company—and they have three children and a white Labrador, Mia, who is blind from retinal dystrophy. He is also a retired martial artist, philosopher, and health enthusiast. About 4DMT 4DMT is a clinical-stage genetic medicines company focused on harnessing the full potential of genetic therapies for large market diseases, particularly in ophthalmology (wet AMD and DME) and pulmonology (cystic fibrosis lung disease). Therapeutic Vector Evolution (TVE): 4DMT's proprietary vector platform leverages the Nobel Prize–winning technology of directed evolution to create customized viral vectors. This approach propels a diverse product pipeline aimed at revolutionizing medicine with potentially curative therapies for millions of patients.  

Aké boli tie najlepšie knihy roka 2024? V našej ankete odpovedajú: Alenka Petejová (architektka) Ján Hreško (filozof a pedagóg) Katarína Zemčík (projektová manažérka ReFormatio) Richard Vávra (Archívny chlapec) Kristína Gburová (turistická sprievodkyňa) Oliver Zajac (historik) Zuzka Lenartová (psychologička) Lukáš Bajgar (Starý Bral) Spomíname: Tvorivý akt: Spôsob bytia (Rick Rubin) Umenie blízkosti (Monika Kompaníková, Ján Hrustič) Všetko čo nás spája: Príbeh slovenskej Vietnamky (Kvet Nguyen) V balíkoch hrklo (Lyrik H) Kráľ Lear (William Shakespeare) Teorie spolehlivosti (Ivan Diviš) Pôvod kultúry (René Girard) Premenená na hudbu (Katarína Džunková) Posledné leto v meste (Gianfranco Calligarich) Sofia Copolla Archive (Sofia Copolla) Takové maličkosti (Claire Keegan) Dom (Paco Roca) Pasažier (Cormac McCarthy) Dejiny lásky (Nicol Crausová) Nadácia na rozhraní (Isaac Asimov) Kim Čijong (ročník 82) (Čo Namdžu) Ťažké časy v Číne (Pavol Dvořák) Zabijaci v móde (Alden Wicker) Bardejovské potulky: Dejiny inak (Peter Harčar, Lucia Guthová) Putovanie ľudí Knihy (Olga Tokarczuk) Šógun (James Clavell) V službách šóguna (Frederik Cryns) Mýty naše Slovenské (Eduard Krekovič, Elena Mannová, Eva Krekovičová) Natašin tanec: Kultúrne dejiny Ruska (Orlando Figes) Předminulé století: Evropa v politice a kultuře 19. století (Jiří Hanuš, Vít Hloušek) Čo sa vám stalo? (Bruce D. Perry, Oprah Winfrey) Ty krásna temná Vanesa (Kate Elizabeth Russell) Komnata ozvien (John Boyne) Smrť vo Viedni (Frank Tallis) Ľad (Ilona Wiśniewska) Slovník ztracených slov (Pip Williams) Poslední jednorožec (Peter S. Beagle) Cesta domů (Peter S. Beagle) Krčmářova píseň (Peter S. Beagle) William Shakespeare: Dílo The Mythmakers (John Hendrix) The Collective Poems of J. R. R. Tolkien (Christina Scull, Wayne G. Hammond) ČITATEĽSKÝ DENNÍK mudrovanie o knihách, komiksoch a preplnených poličkách. (23. 12. 2024) Mix & zvučka: Jakub Lenart Podporiť nás môžete tu: cutt.ly/fwN6NGZK www.kandelaber.sk

In this podcast, expert clinicians will discuss new efficacy, safety, and durability data on dosing regimens, delivery systems, and emerging therapies for the treatment of neovascular age-related macular degeneration (nAMD). https://www.healio.com/cme/mededtalks/ophthalmology/20240729/2-the-retina-radar-with-dr-arshad-khanani-namd-management-in-2024

Recent studies have proven the therapeutic viability of a different approach in treating retinal vascular diseases. Join Dr. John Kitchens, Dr. Margaret Chang, and Dr. David Chin Yee as they discuss their clinical experiences using a therapy with a novel mechanism of action in patients with nAMD and DME. And, learn how they approach managing patients with macular edema. This special episode of New Retina Radio, and its content, is supported by Genentech USA, Inc.

CME credits: 0.25 Valid until: 07-06-2025 Claim your CME credit at https://reachmd.com/programs/cme/improving-adherence-and-persistence-with-durable-anti-vegf-therapies-for-namd/18068/ This case consult with Dr Do and Dr Kaiser will consider a treatment-experienced patient referred for a 2nd opinion with decreased vision and prior diagnosis of neovascular AMD (nAMD). Dr Do and Dr Kaiser will discuss the recently approved anti-vascular endothelial growth factor (VEGF) agents with greater durability and longer dosing intervals that can decrease treatment burden. These retina specialists will evaluate the treatment responses in this patient and discuss whether to modify dosing intervals or switch therapies. This case illustrates the burden of care for patients with neovascular AMD (nAMD), and shows how to use the more durable anti-VEGF therapies in clinical practice to reduce treatment burden.=

The Cochrane Eyes and Vision US Project prepares and maintains reviews across a wide range of conditions. These include neovascular age-related macular degeneration and their new review of its treatment by anti-vascular endothelial growth factor biosimilars was published in June 2024. Here's one of the authors, Sueko Ng from the Department of Ophthalmology in the University of Colorado Anschutz Medical Campus in the USA, to tell us more about the condition and this treatment.

The Cochrane Eyes and Vision US Project prepares and maintains reviews across a wide range of conditions. These include neovascular age-related macular degeneration and their new review of its treatment by anti-vascular endothelial growth factor biosimilars was published in June 2024. Here's one of the authors, Sueko Ng from the Department of Ophthalmology in the University of Colorado Anschutz Medical Campus in the USA, to tell us more about the condition and this treatment.

The Cochrane Eyes and Vision US Project prepares and maintains reviews across a wide range of conditions. These include neovascular age-related macular degeneration and their new review of its treatment by anti-vascular endothelial growth factor biosimilars was published in June 2024. Here's one of the authors, Sueko Ng from the Department of Ophthalmology in the University of Colorado Anschutz Medical Campus in the USA, to tell us more about the condition and this treatment.

CME credits: 1.00 Valid until: 02-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/get-real-a-guide-to-evolving-treatment-of-namd-and-dme-using-real-world-data/16619/ Let's get real. Clinical trial data can be difficult to apply to retina practices. Patient populations are often limited, and injection schedules are strictly enforced in clinical trial settings. Fortunately, real-world evidence based on large registry data are amassing to shed light on current treatment practices and their effects on patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Join our expert faculty as they reveal real-world experience with anti-vascular endothelial growth factor (VEGF) therapy and novel dual inhibition therapy and assess how this information might be used to guide practice changes.=

CME credits: 0.50 Valid until: 25-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/extending-treatment-durability-with-next-generation-neovascular-amd-therapies/18067/ The CME News Broadcast webinar will engage retina specialists and treating ophthalmologists with education needed to integrate the new durable anti-vascular endothelial growth factor (VEGF) therapies for neovascular AMD (nAMD) into clinical practice. This will include recent data on the efficacy, safety, and durability of these new therapies and the imaging approaches that can be used to facilitate monitoring of nAMD disease progression and treatment success. This activity will create understanding of the new durable therapies and how they can extend dosing intervals. The expert faculty will discuss the latest data on new anti-VEGF therapies with the potential to reduce treatment burden and improve vision outcomes. =

We discuss the feasibility of using home OCT vs. a treat and extend approach in a clinical trial of faricimab in neovascular AMD with Dr. Kevin Blinder of the Retina Institute in Saint Louis, Mo and Profesor of Ophthalmology at Washington University School of Medicine.

Please visit answersincme.com/HEQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses how to optimize the use of intravitreal anti-vascular endothelial growth factor (VEGF) therapies in patients with neovascular age-related macular degeneration (nAMD) using a case-based approach with perspectives from a patient. Upon completion of this activity, participants should be better able to: Describe the latest evidence for anti-VEGF therapies used in the treatment of nAMD; Outline practical strategies to optimize the use of anti-VEGF therapies in the management of nAMD; and Explain the importance of shared decision-making in the management of nAMD.

Please visit answersincme.com/HEQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses how to optimize the use of intravitreal anti-vascular endothelial growth factor (VEGF) therapies in patients with neovascular age-related macular degeneration (nAMD) using a case-based approach with perspectives from a patient. Upon completion of this activity, participants should be better able to: Describe the latest evidence for anti-VEGF therapies used in the treatment of nAMD; Outline practical strategies to optimize the use of anti-VEGF therapies in the management of nAMD; and Explain the importance of shared decision-making in the management of nAMD.

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-for-durable-treatment-of-dme/15854/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/reconsidering-the-algorithm-treatment-resistant-dme/15860/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/reconsidering-the-algorithm-dme/15859/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/reconsidering-the-algorithm-namd/15858/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/a-look-at-the-numbers-cost-of-durable-treatments-in-retinal-disease/15857/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/real-world-outcomes-with-durable-treatments-for-retinal-diseases/15855/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/a-closer-look-at-real-world-strategies-for-treatment-resistant-dme/15856/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-for-durable-treatment-of-namd/15853/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

CME credits: 1.00 Valid until: 15-09-2024 Claim your CME credit at https://reachmd.com/programs/cme/real-world-treatment-of-retinal-disease/15852/ The approval of new, more durable treatments is an exciting development for the management of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), but how do these therapies and their unique mechanisms stack up outside of clinical trials? Join Dr. Durga Borkar, Dr. Sabin Dang, Dr. Jayanth Sridhar, and Dr. Christina Weng as they discuss these new treatments and the emerging data surrounding their use in the real world.

In this podcast, expert faculty will discuss the management of nAMD.

Please visit answersincme.com/XVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in ophthalmology discuss intravitreal anti–vascular endothelial growth factor (VEGF) injections for neovascular age-related macular degeneration (nAMD). Upon completion of this activity, participants should be better able to: Describe the latest evidence for anti-vascular endothelial growth factor (anti-VEGF) therapies used in the treatment of nAMD; and Outline practical strategies to optimize the use of anti-VEGF therapies in the management of nAMD.

Please visit answersincme.com/XVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in ophthalmology discuss intravitreal anti–vascular endothelial growth factor (VEGF) injections for neovascular age-related macular degeneration (nAMD). Upon completion of this activity, participants should be better able to: Describe the latest evidence for anti-vascular endothelial growth factor (anti-VEGF) therapies used in the treatment of nAMD; and Outline practical strategies to optimize the use of anti-VEGF therapies in the management of nAMD.

Dr. Avni Finn, retina specialist affiliated with Vanderbilt Eye Institute shares her experiences with new modalities and ways to optimize/personalize nAMD treatment in both Treatment Naïve and Switch patients. Click here to listen to the podcast.

In this podcast, expert clinicians will discuss long-acting injectables in nAMD management.

Please visit answersincme.com/AXS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Dr. Adam S. Wenick, an expert in ophthalmology, discusses treatment adherence in neovascular age-related macular degeneration (nAMD). Upon completion of this activity, participants should be better able to: Recognize the clinical impact of available intravitreal vascular endothelial growth factor– (VEGF-) targeted therapies for neovascular age-related macular degeneration (nAMD); Outline practical strategies to individualize intravitreal VEGF-targeted treatment selection and dosing for patients with nAMD; and Review patient counseling approaches to improve treatment adherence to intravitreal VEGF-targeted therapies for nAMD.

Please visit answersincme.com/RUA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses strategies for using intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of available intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration (nAMD); Outline practical strategies to individualize intravitreal VEGF-targeted treatment selection and dosing for patients with nAMD; and Describe management strategies to optimize outcomes for patients receiving intravitreal VEGF-targeted therapy for nAMD.

CME credits: 0.25 Valid until: 08-09-2023 Claim your CME credit at https://reachmd.com/programs/cme/retina-clinic-current-treatment-options-in-namd/13983/ With the availability of multiple novel treatment options, how do we decide which is best for each patient with neovascular age-related macular degeneration? Join Dr. Arshad Khanani and Dr. Carl Danzig as they discuss their approach to treatment based on the latest clinical evidence.

Please visit answersincme.com/BJH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in retinal disease discusses strategies for treating patients with intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of available intravitreal VEGF-targeted therapies for neovascular age-related macular degeneration (nAMD); Outline practical strategies to individualize intravitreal VEGF-targeted treatment selection and dosing for patients with nAMD; and Describe management strategies to optimize outcomes for patients receiving intravitreal VEGF-targeted therapy for nAMD.

HEALTH NEWS   Cocoa flavanols may be able to reduce blood pressure Cool room temperature inhibited cancer growth in mice Smells experienced in nature evoke positive wellbeing Healthy lifestyle may buffer against stress-related cell aging, study says Zinc plus antioxidants: A cost-effective solution to macular degeneration? Passive exercise offers same brain health benefits as active movements, study finds Cocoa flavanols may be able to reduce blood pressure University of Surrey (UK), July 23, 2022 A recent study found that cocoa flavanols can effectively lower blood pressure in people with ideal blood pressure, but not when it was already low, as well as reduce arterial stiffness.  Researchers of the current study note that previous controlled clinical intervention studies have demonstrated the blood pressure-decreasing and arterial stiffness-reducing effects of cocoa flavanols (CF) in healthy humans. However, as these studies were in tightly controlled settings, the researchers wanted to see how well this intervention played out in real-life scenarios. The researchers used an n-of-1 study design, where a small number of participants were exposed to the same intervention or the placebo multiple times. They then compared the results for each individual as well as between individuals.  The study included eleven healthy adults who received alternating doses of cocoa flavanol capsules and placebo capsules for eight days.  The results showed that cocoa flavanols were effective in lowering blood pressure and reducing arterial stiffness.  One concern about using cocoa flavanols to lower blood pressure is the risk of the blood pressure dropping too low. However, in this study, researchers found that the cocoa had less impact when blood pressure was lower, indicating it was a potentially safe intervention.  Prof. Christian Heiss, study author and professor of cardiovascular medicine, explained to MNT:  “The study confirms that cocoa flavanols can lower blood pressure and improve arterial stiffness. The new thing is that it does so in the normal life of healthy people and only lowers it if it is ‘high' even in the ‘normal range.” Cool room temperature inhibited cancer growth in mice Karolinska Institutet, August 5, 2022 Turning down the thermostat seems to make it harder for cancer cells to grow, according to a study in mice by researchers at Karolinska Institutet in Sweden. The study, published in the journal Nature, found that chilly temperatures activate heat-producing brown fat that consumes the sugars the tumors need to thrive. Similar metabolic mechanisms were found in a cancer patient exposed to a lowered room temperature. "We found that cold-activated brown adipose tissue competes against tumors for glucose and can help inhibit tumor growth in mice," says Professor Yihai Cao at the Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, and corresponding author. "Our findings suggest that cold exposure could be a promising novel approach to cancer therapy, although this needs to be validated in larger clinical studies." The study compared tumor growth and survival rates in mice with various types of cancer, including colorectal, breast and pancreatic cancers, when exposed to cold versus warm living conditions. Mice acclimatized to temperatures of 4 degrees Celsius had significantly slower tumor growth and lived nearly twice as long compared with mice in rooms of 30 degrees Celsius. They found that cold temperatures triggered significant glucose uptake in brown adipose tissue, also known as brown fat, a type of fat that is responsible for keep the body warm during cold conditions. At the same time, the glucose signals were barely detectable in the tumor cells. When the researchers removed either the brown fat or a protein crucial for its metabolism called UCP1, the beneficial effect of the cold exposure was essentially wiped out and the tumors grew at a pace on par with those that were exposed to higher temperatures. Similarly, feeding tumor-bearing mice with a high sugar drink also obliterated the effect of cold temperatures and restored tumor growth. "Interestingly, high sugar drinks seem to cancel out the effect of cold temperatureson cancer cells, suggesting that limiting glucose supply is probably one of the most important methods for tumor suppression," Yihai Cao says.   Smells experienced in nature evoke positive wellbeing University of Kent (UK), August 5, 2022 Smells experienced in nature can make us feel relaxed, joyful, and healthy, according to new research led by the University of Kent's Durrell Institute of Conservation and Ecology (DICE). Smells were found to play an important role in delivering well-being benefits from interacting with nature, often with a strong link to people's personal memories, and specific ecological characteristics and processes (e.g. fallen leaves rotting in the winter). Researchers found that smells affected multiple types of human well-being, with physical well-being noted most frequently, particularly in relation to relaxation, comfort and rejuvenation. Absence of smell was also perceived to improve physical well-being, providing a cleansing environment due to the removal of pollution and unwanted smells associated with urban areas, and therefore enabling relaxation. Relaxation reduces stress and lowers cortisol levels, which is often linked to a multitude of diseases, and so these findings could be particularly significant to public health professionals. The research, carried out in woodland settings across four seasons, also found that smells evoked memories related to childhood activities. Many participants created meaningful connections with particular smells, rather than the woodland itself, and associated this with a memorable event. This, in turn, appeared to influence well-being by provoking emotional reactions to the memory.   Healthy lifestyle may buffer against stress-related cell aging, study says University of California at San Francisco  July 29, 2022   A new study from UC San Francisco is the first to show that while the impact of life's stressors accumulate overtime and accelerate cellular aging, these negative effects may be reduced by maintaining a healthy diet, exercising and sleeping well.    "The study participants who exercised, slept well and ate well had less telomere shortening than the ones who didn't maintain healthy lifestyles, even when they had similar levels of stress," said lead author Eli Puterman, PhD, assistant professor in the department of psychiatry at UCSF. "It's very important that we promote healthy living, especially under circumstances of typical experiences of life stressors like death, caregiving and job loss."   In the study, researchers examined three healthy behaviors –physical activity, dietary intake and sleep quality – over the course of one year in 239 post-menopausal, non-smoking women. In women who engaged in lower levels of healthy behaviors, there was a significantly greater decline in telomere length in their immune cells for every major life stressor that occurred during the year. Yet women who maintained active lifestyles, healthy diets, and good quality sleep appeared protected when exposed to stress – accumulated life stressors did not appear to lead to greater shortening.    "This is the first study that supports the idea, at least observationally, that stressful events can accelerate immune cell aging in adults, even in the short period of one year. Exciting, though, is that these results further suggest that keeping active, and eating and sleeping well during periods of high stress are particularly important to attenuate the accelerated aging of our immune cells," said Puterman.  Zinc plus antioxidants: A cost-effective solution to macular degeneration? University of Washington and University College London, July 30, 2022 A formula supplement containing anti-oxidants plus zinc appears to be cost-effective in slowing the progression of the ‘wet' form of the most common degenerative eye disease, finds a new study in British Journal of Ophthalmology. The cost savings and effectiveness of the supplement in advanced (category 4) cases of neovascular (wet-form) Age Related Macular Degeneration (nAMD) are such that their use should be considered in public health policy, recommend the multi-centre study team on behalf of the UK Electronic Medical Record (EMR) AMD Research Team.  Category 4 individuals who already had nAMD in one eye, showed a cost saving of nearly €3250 (£3000) per patient over the lifetime of treatment, compared to those not given supplements. The Age Related Eye Disease Study (AREDS) formula supplements also increased quality-adjusted life years (QALYs) by 0.16. “AREDS supplements are a dominant cost-effective intervention for category 4 AREDS patients, as they are both less expensive than standard care and more effective, and therefore should be considered for public funding,” wrote lead researcher Dr. Adnan Tufail. The study examined the use of AREDS formulation 1 and formulation 2 supplements.  AREDS 1 contained 80milligrams (mg) zinc, 2 mg copper, 500 mg vitamin C, 15 mg beta-carotene, 400 IU vitamin E. AREDS 2 reduced the amount of zinc to 25 mg, excluded beta-carotene (due to potential higher cancer risk in smokers), and added 10 mg lutein, 2 mg zeaxanthin, 1000 mg omega-3 fatty acids (650 mg docosahexaenoic acid and 350 mg eicosapentaenoic acid). These findings are consistent with previous research demonstrating the effectiveness of AREDS supplementss. Consequently, the researchers advocate the use of supplements to reduce the necessity for ranibizumab injections, which is the standard NHS treatment for AMD.   Passive exercise offers same brain health benefits as active movements, study finds University of Western Ontario, August 4, 2022 A new study by kinesiology graduate students from Western has found passive exercise leads to increased cerebral blood flow and improved executive function, providing the same cognitive benefits as active exercise. Published in Psychophysiology, the study is the first to look at whether there would be benefits to brain health during passive exercise where a person's limbs are moved via an external force—in this case, cycle pedals pushed by a mechanically driven flywheel.  During a 20-minute session with healthy young adults, the team found an improvement in executive function of the same magnitude for both the passive and the active exercise conditions, without an increase in heart rate or diastolic blood pressure.  Executive function is a higher-order cognitive ability that allows people to make plans and supports the activities of daily living. People who have mild cognitive impairments, such as people experiencing symptoms of early-stage Alzheimer's, can find their executive function negatively affected.  Previous research has documented that active exercise, where a person activates their muscles of their own volition, can increase blood flow to the brain and improve executive function. Passive exercise also increases blood flow to the brain, but this is significantly less documented.   During passive exercise, a person's limbs move and their muscle receptors are being stretched. That information is sent to the brain, indicating that more blood is needed in the moving areas of the body and in connected regions of the brain. This increase in cerebral blood flow, while significantly less than with active exercise, produced executive function improvements of a similar magnitude—an exciting result for the researchers.  "The potential impact for people with limited or no mobility could be profound. If done regularly, the increase in blood flow to the brain and resultant improvement in executive function will, optimistically, become a compounding effect that has a significant impact on cognitive health and executive function," Heath explained. 

The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Nancy Holekamp discuss the efficacy and safety of therapies targeting Ang-2 in DME.

The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Arshad Khanani discuss the efficacy and safety of therapies targeting Ang-2 in nAMD.

The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Judy Kim discuss the Tie2 pathway and its role in the pathophysiology of retinal vascular diseases.

The newly approved ophthalmic drug faricimab (Vabysmo) has already made waves by being the first of its drug class to be approved for both diabetic macular edema (DME) and neovascular age-related degeneration (nAMD). A new phase 4 clinical trial from Genentech seeks to expand on the efficacy of the drug in patients with DME from underrepresented populations. The efficacy and safety of faricimab will be assessed in patients from African American, Hispanic, Latin American, and Indigenous communities throughout the Elevatum trial, which Matthew Cunningham, MD, of the Florida Retina Institute, believes to be the first industry-sponsored assessment regarding representation in DME trials. For this episode of DocTalk, Cunningham sits down with managing editor Kevin Kunzmann to speak to the issue of representation in DME and other ophthalmology trials, and how DME disproportionately affects underrepresented populations. Furthermore, Cunningham details the burdens that patients from underrepresented communities face with trial inclusion standards.

Join these renowned experts for a panel discussion on how to incorporate into clinical practice the latest treatments for neovascular age-related macular degeneration (nAMD). The panelists will also share the latest outcomes data and their clinical experience using these therapies.

We review current status of clinical research on gene therapy for neovascular AMD and diabetic retinopathy with Dr. Allen Ho, Professor of Ophthalmology, Jefferson Medical College and Wills Eye Hospital.

CME credits: 0.25 Valid until: 31-03-2023 Claim your CME credit at https://reachmd.com/programs/cme/the-future-is-now-new-data-for-namd-and-dme-in-vascular-integrity/13280/ Second-generation intravitreal agents that incorporate new pathogenic targets have emerged for the treatment of retinal diseases. What are these targets, and how should these new medicines be used in clinical practice? Join Dr. Diana Do and Dr. John Wells as they discuss novel mechanisms for therapeutic control of neovascular age-related macular degeneration and diabetic macular edema and how to incorporate these new agents into clinical practice.

CME credits: 0.25 Valid until: 31-03-2023 Claim your CME credit at https://reachmd.com/programs/cme/the-future-is-now-new-data-for-namd-and-dme-in-vascular-integrity/13280/ Second-generation intravitreal agents that incorporate new pathogenic targets have emerged for the treatment of retinal diseases. What are these targets, and how should these new medicines be used in clinical practice? Join Dr. Diana Do and Dr. John Wells as they discuss novel mechanisms for therapeutic control of neovascular age-related macular degeneration and diabetic macular edema and how to incorporate these new agents into clinical practice.

We review long term results of the Port Delivery System for treating neovascular AMD  with Dr. David Eichenbaum of Retina Vitreous Associates of Florida, Collaborative Associate Professor University of South Florida.

We review the results of the phase I Graybug study Altissimo using sustained release tyrosinase kinase inhibitor for long term treatment of neovascular AMD with Dr. Veeral Sheth, Chicago, Illinois, Assistant Clinical Professor University of Illinois at Chicago.

We discuss the DAVIO trial of EYP-1901 with Dr. Jay S. Duker, Chief Operating Officer of Eyepoint Pharmaceuticals.

Discussion of variations in injection volume for treatment of nAMD, DME and MERVO with Roger Goldberg, M.D., M.B.A.,  Bay Area Retina Associates

We examine the role of residual IRF and SRF in visual acuity results in treating nAMD. Dr. David Eichenbaum of Retina Vitreous Associates of Florida, Collaborative Associate Professor University of South Florida reviews the results of the Hawk and Harrier trials.

Diana Do, MD, Professor of Ophthalmology, Vice Chair Clinical Affairs, Department of Ophthalmology, Stanford University, Byers Eye Institute.

Join us in a discussion with Dr. Charles Wykoff & Karl Csaky MD, PhD on Faricimab for DME and nAMD. Interpreting the Durability Signals from the Phase 3 Programs.

Join us as Dr. Carmen Puliafito and Charles Wykoff MD, PhD speak about the results. 1 of 3 total parts to "Interpreting Faricimab Phase 3 Data in DME & nAMD"